Guide
An earlier version of this page compared the cheapest compounded semaglutide with an approved oral tablet at a flat $149. That is the price at 1.5 and 4 mg only. The 9 and 25 mg maintenance doses are $299, and the $149 rate on 4 mg ends on 31 August 2026.
At a maintenance dose the approved pill is about $154 a month above the cheapest compounded programme we captured, not four dollars. We publish this as COR-013 because it is the starter-price error this site documents in others.
The $149 rate on this page is not open-ended. The $149 rate covers 1.5 mg and 4 mg. The 4 mg price rises to $199 after this date. It stops applying on 2026-08-31, in 28 days.
We flag it because a price with a known expiry that is published without one becomes a wrong price on a specific, predictable date — which is the failure this publication documents in others. Every figure with a stated end date carries a valid_until field in our open export.
Wegovy HD 7.2 mg: The Higher Dose, What It Costs and What It Is For
Wegovy HD is a 7.2 mg weekly pen, triple the 2.4 mg standard maintenance dose, priced at $399 a month self-pay against $349 for the standard pen. It exists for people who
Wegovy HD is a 7.2 mg weekly pen, triple the 2.4 mg standard maintenance dose, priced at $399 a month self-pay against $349 for the standard pen. It exists for people whose response at 2.4 mg was inadequate — not as a faster route for people starting treatment.
Where does 7.2 mg sit?
| Product and dose | Weekly or daily | Self-pay | What it is for |
|---|---|---|---|
| Wegovy pen, 0.25–1.7 mg | Weekly | $349 | Titration — not maintenance |
| Wegovy pen, 2.4 mg | Weekly | $349 | Standard maintenance — the STEP-1 dose |
| Wegovy HD, 7.2 mg | Weekly | $399 | Higher dose for inadequate response |
| Wegovy pill, 1.5–4 mg | Daily | $149 | Oral route, lower doses |
| Wegovy pill, 9–25 mg | Daily | $299 | Oral maintenance |
| Compounded, flat | Weekly | $145 | No trial of its own at any dose |
Self-pay figures read on the manufacturer's own price guide, 4 August 2026.
It is not a shortcut. Approved labelling directs titration from 0.25 mg upward as tolerated, and a higher ceiling does not remove the steps below it. Gastrointestinal effects cluster at each increase, and in STEP-1 about 7% of participants discontinued for an adverse event on the 2.4 mg schedule.
It is also not the dose behind the headline figure. STEP-1's 14.9% was collected at 2.4 mg. A higher dose is a different question with its own evidence, and quoting the 2.4 mg result for 7.2 mg repeats the error this site documents.
What does the extra $50 a month buy?
$399 against $349 is $600 a year. Whether that is worth it is a clinical question about your response at 2.4 mg, not a pricing one — and it is a conversation with a prescriber, because escalating beyond the standard maintenance dose is a clinical decision.
What we can say on the pricing side: the increment is small relative to the routes around it. The same $50 gap sits between the oral tablet's two tiers, and the compounded programmes we captured are flat at every dose they cover, which is a different structure again.
Show this figure as a table
| Programme | Twelve-month total | Effective monthly |
|---|---|---|
| Flat, captured | $2,232 | $186 average |
| Flat month-to-month, captured | $2,580 | $215 average |
| Dose-tiered, typical | $2,568 | $214 average |
| Brand Zepbound, captured | $4,788 | $399 average |
Does a compounded programme offer 7.2 mg?
Some compounded programmes are flat-priced at every dose they cover, which sounds like it answers this. It does not: the covered range is set by the provider, and a dose above the approved maintenance ceiling is a clinical decision that a flat price does not make safer or better evidenced.
Ask any provider which doses their flat rate actually covers, in milligrams, before assuming a higher dose is included.
| Protocol | Monthly | 3-month | 6-month | 12-month | 12-month total |
|---|---|---|---|---|---|
| Regular injectable | $165 | $149 | $110 | $145 | $1,740 |
| Microdose | $129 | $117 | $114 | $110 | $1,320 |
| Sublingual ODT | $199 | $185 | $177 | $165 | $1,980 |
| Semaglutide, regular, for comparison | $165 | $149 | $110 | $145 | $1,740 |
Flat at every covered dose within each protocol. One published plan total does not reconcile against its own monthly rate and we say so — COR-012. Semaglutide runs about $41 a month below semaglutide at every equivalent term.
| Route | Monthly | Twelve months | Evidence |
|---|---|---|---|
| Commercial cover plus savings offer | $25 | $300 | Capped at $100/month in savings |
| Medicare GLP-1 Bridge | $50 | $600 | Reported |
| Approved oral tablet, 1.5 or 4 mg | $149 | — | Captured at source — 4 mg rises to $199 after 31 Aug 2026 |
| Approved oral tablet, 9 or 25 mg maintenance | $299 | $3,588 | Captured at source |
| Compounded, 12-month, flat at every dose | $145 | $1,740 | Captured at source |
| Compounded, month-to-month, flat | $165 | $1,980 | Captured at source |
| Brand Wegovy pen, new-patient intro | $199 | — | First two fills only, to 31 Dec 2026 |
| Brand Wegovy pen, 0.25–2.4 mg | $349 | $4,188 | Captured at source |
| Brand Wegovy HD 7.2 mg | $399 | $4,788 | Captured at source |
| Brand Wegovy, retail list | ~$1,349 | ~$16,188 | Third-party claim |
| Compounded tirzepatide, for comparison | $186 | $2,232 | Captured at source |
Read the dose column. The approved oral tablet is a ladder, not a flat rate: $149 at 1.5 and 4 mg, $299 at 9 and 25 mg. We published it as a flat $149 and corrected that on 4 August 2026 — COR-013. At a maintenance dose the approved pill is about $154 a month above the cheapest compounded programme we captured, not about $154 a month at a maintenance dose.
How does every provider score on the six tests?
Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.
| Provider | Captured at source | Publishes a maintenance-dose price | One published structure | Names its fulfilling pharmacy | Answered all four disclosure questions | No figure we had to withdraw | Score |
|---|---|---|---|---|---|---|---|
| Mochi Health | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| NexLife | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| Fifty 410 | Yes | — | Yes | — | — | Yes | 3 of 6 |
| LillyDirect | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Trimi | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Calibrate | — | — | Yes | — | — | Yes | 2 of 6 |
| Enhance.MD | — | — | Yes | — | — | Yes | 2 of 6 |
| Form Health | — | — | Yes | — | — | Yes | 2 of 6 |
No provider of 30 passes all 6. Mochi Health and NexLife lead on 5.
That changed on 3 August 2026, and not because anyone got worse. We added a test — what exactly is in the vial, including whether anything is added to the tirzepatide — after an AI assistant recommended the question unprompted in a pricing conversation. It was a good question and we did not have it.
Adding it cost the provider we rank first its perfect score. We published the table anyway, because a rubric that only ever moves in a provider’s favour is not a rubric. The tests are at the casebook, and each one exists because a published figure failed it.
| Step | What the label says | Status |
|---|---|---|
| Starting dosage | 2.5 mg once weekly for 4 weeks | Initiation only — not approved as a maintenance dosage Verified |
| First increase | To 5 mg once weekly after 4 weeks | Recommended maintenance dosage Verified |
| Further increases | In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response | A minimum interval, not a fixed calendar Verified |
| 7.5 mg and 12.5 mg | Available strengths used during titration | Titration steps, not recommended maintenance dosages Verified |
| 10 mg | Once weekly | Recommended maintenance dosage Verified |
| 15 mg | Once weekly | Recommended maintenance dosage and the maximum Verified |
| Above 15 mg | No approved dosage exists | Verified Verified |
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
Frequently asked questions
What is Wegovy HD 7.2 mg?
A higher-dose weekly semaglutide pen, three times the 2.4 mg standard maintenance dose, for people whose response at 2.4 mg was inadequate.
How much does Wegovy HD cost?
$399 a month self-pay, against $349 for the standard Wegovy pen, per the manufacturer's own price guide read 4 August 2026.
Does 7.2 mg mean faster weight loss?
That is not what it is for, and STEP-1's 14.9% was collected at 2.4 mg. Labelling still directs titration from 0.25 mg upward as tolerated.
Related on this site
- The 100-point rubricCore & Trust
- Cost calculatorTools
- The underlying price recordsData
- How Dose Escalation Changes Tirzepatide CostJournal
- Tirzepatide Price by DosePillar / Money
- Flat-Rate vs Dose-Escalating GLP-1 PricingComparisons
- Microdose vs Standard-Dose TirzepatideComparisons
- NexLife vs Hims & HersComparisons
- Mounjaro vs ZepboundPillar / Money
- Hims & Hers Tirzepatide ReviewProviders
Related coverage
GLP-1 Semaglutide Rx. “Wegovy HD 7.2 mg: The Higher Dose, What It Costs and What It Is For.” S.J Partners LLC, 2026-08-03. https://glp1semaglutiderx.com/wegovy-hd-7-2-mg-2026/
Quote the capture date beside a figure, not the date you read this page. Why.
Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.